Amylyx Pharmaceuticals (AMLX) Q1 2025 earnings summary

Executive summary

• Advanced pivotal clinical trials for Avexitide, AMX0035, and AMX-114/AMX0114, with first dosing in LUCIDITY and LUMINA trials and positive Phase II data for AMX0035 in Wolfram syndrome.

• Ceased marketing and sales of RELYVRIO/ALBRIOZA in April 2024, shifting focus to R&D and implementing a 70% workforce reduction.

• Raised $65.5 million in a January 2025 public offering, extending cash runway through end of 2026.

Financial highlights

• Ended Q1 2025 with $204.1 million in cash, cash equivalents, and marketable securities, including $65.5 million from a public offering.

• No product revenue in Q1 2025 after discontinuing RELYVRIO/ALBRIOZA; net loss narrowed to $35.9 million from $118.8 million in Q1 2024.

• R&D expenses were $22.1 million (down 40% year-over-year); SG&A expenses were $15.7 million (down 73%).

• Non-cash stock-based compensation was $6.8 million, down from $9.9 million in Q1 2024.

• $6 million in cash used for product rebates and purchase commitments related to discontinued products; $3.1 million in residual obligations expected in 2025.

Outlook and guidance

• Cash runway expected through end of 2026, supporting clinical milestones and commercial preparations for Avexitide.

• Topline data from LUCIDITY (Avexitide) expected in H1 2026; Helios (Wolfram) week 48 data imminent; Orion (PSP) phase II-B data in Q3 2025; Lumina (AMX-114/AMX0114 in ALS) early data in 2025.

• Commercial launch of Avexitide in PBH targeted for 2027, pending approval.